Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Pharmacol Rep ; 76(3): 572-584, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38664334

ABSTRACT

BACKGROUND: Essential phospholipids (EPL) are hepatoprotective. METHODS: The effects on interleukin (IL)-6 and -8 secretion and on certain lipid-metabolizing enzymes of non-cytotoxic concentrations of EPL (0.1 and 0.25 mg/ml), polyenylphosphatidylcholine (PPC), and phosphatidylinositol (PtdIns) (both at 0.1 and 1 mg/ml), compared with untreated controls, were assessed in human hepatocyte cell lines (HepG2, HepaRG, and steatotic HepaRG). RESULTS: Lipopolysaccharide (LPS)-induced IL-6 secretion was significantly decreased in HepaRG cells by most phospholipids, and significantly increased in steatotic HepaRG cells with at least one concentration of EPL and PtdIns. LPS-induced IL-8 secretion was significantly increased in HepaRG and steatotic HepaRG cells with all phospholipids. All phospholipids significantly decreased amounts of fatty acid synthase in steatotic HepaRG cells and the amounts of acyl-CoA oxidase in HepaRG cells. Amounts of lecithin cholesterol acyltransferase were significantly decreased in HepG2 and HepaRG cells by most phospholipids, and significantly increased with 0.1 mg/ml PPC (HepaRG cells) and 1 mg/ml PtdIns (steatotic HepaRG cells). Glucose-6-phosphate dehydrogenase activity was unaffected by any phospholipid in any cell line. CONCLUSIONS: EPL, PPC, and PtdIns impacted the secretion of pro-inflammatory cytokines and affected amounts of several key lipid-metabolizing enzymes in human hepatocyte cell lines. Such changes may help liver function improvement, and provide further insights into the EPL's mechanism of action.


Subject(s)
Hepatocytes , Lipid Metabolism , Phospholipids , Humans , Hepatocytes/metabolism , Hepatocytes/drug effects , Phospholipids/metabolism , Hep G2 Cells , Lipid Metabolism/drug effects , Lipopolysaccharides/pharmacology , Cytokines/metabolism , Interleukin-6/metabolism , Interleukin-8/metabolism , Cell Line
2.
Lipids Health Dis ; 21(1): 91, 2022 Sep 24.
Article in English | MEDLINE | ID: mdl-36153592

ABSTRACT

BACKGROUND: Essential phospholipids (EPL) have hepatoprotective effects across many liver diseases/conditions. The impact of EPL on hepatocyte function in vitro was investigated. METHODS: Effects of noncytotoxic concentrations of EPL (0.1 and 0.25 mg/ml), and its constituents, polyenylphosphatidylcholine (PPC) and phosphatidylinositol (PI) (both at 0.1 and 1 mg/ml), on membrane fluidity, apoptosis and extracellular transport versus controls were investigated in human hepatocyte cell lines (HepG2, HepaRG, steatotic HepaRG).  RESULTS: Significantly increased membrane fluidity occurred with all 3 phospholipids (PLs) in HepG2 cultures, and with PI (1 mg/ml) in steatotic HepaRG cells. Significantly decreased tamoxifen-induced apoptosis was observed in HepG2 cells with EPL, PPC and PI. Breast cancer resistance protein (BCRP) activity was significantly increased by EPL and PI in HepG2 cells. Multidrug resistance-associated protein 2 (MRP-2) activity was unaffected by any PL in HepG2 cells, and significantly increased by EPL, PI and PPC (1 mg/ml) in HepaRG cells, and by PI (1 mg/ml) in steatotic HepaRG cells. Bile salt export protein (BSEP) activity in HepG2 cells and steatotic HepaRG cells was significantly increased by EPL (0.25 mg/ml), and PPC (both concentrations), but not by PI. The PLs had no effects on HepaRG cell BSEP activity. P-glycoprotein (P-GP) activity was significantly increased by all compounds in HepG2 cells. PI (1 mg/ml) significantly increased P-GP activity in HepaRG and steatotic HepaRG cells. CONCLUSIONS: EPL, PPC, and PI increased hepatocyte membrane fluidity, decreased apoptosis and increased hepatocellular export, all of which may improve liver function. These in-vitro investigations provide valuable insights into the mechanism of action of EPL.


Subject(s)
Fatty Liver , Neoplasm Proteins , ATP Binding Cassette Transporter, Subfamily B/metabolism , ATP Binding Cassette Transporter, Subfamily G, Member 2/metabolism , Apoptosis , Bile Acids and Salts/metabolism , Cell Line , Fatty Liver/metabolism , Hepatocytes/metabolism , Humans , Neoplasm Proteins/metabolism , Phosphatidylinositols/metabolism , Tamoxifen/adverse effects , Tamoxifen/metabolism
3.
Bioconjug Chem ; 30(3): 853-860, 2019 03 20.
Article in English | MEDLINE | ID: mdl-30735028

ABSTRACT

Plasmon-resonant nanoparticles provide unprecedented spatiotemporal control over the release of diverse cargoes into cells. Here we compare the loading, release and internalization efficiencies, and effectiveness of post transcriptional gene silencing of hollow gold nanoshells, hollow gold nanocages, and gold nanorods with plasmons tuned to absorb near-infrared light at 800 nm. The hollow gold nanoshells can be loaded with up to three times more siRNA cargo compared to nanocages and nanorods; however, nanorods exhibit the highest efficiency of release of attached siRNA strands when exposed to pulsed 800 nm laser excitation. In cellular treatments, all particles demonstrated efficient internalization into HeLa cells, but the nanoshells and nanocages display the highest downregulation of GFP expression 72 h after treatment. These results provide novel insights into the relative efficiencies of three structurally distinct types of gold nanoparticles as siRNA carriers and we examine different parameters that may influence their efficacy.


Subject(s)
Gold/chemistry , Metal Nanoparticles/chemistry , RNA, Small Interfering/administration & dosage , Endocytosis , Gene Knockdown Techniques , Green Fluorescent Proteins/genetics , HeLa Cells , Humans
4.
Int J Pharm ; 512(1): 87-95, 2016 Oct 15.
Article in English | MEDLINE | ID: mdl-27553779

ABSTRACT

The existence of the blood-brain barrier (BBB) complicates the treatment of many central nervous system (CNS) disorders, including the copper storage disease, Wilson's disease. Its CNS symptoms represent a serious problem, since therapeutics for Wilson's disease do not cross the BBB. One strategy to overcome this obstacle is the transfer of drugs across the BBB with colloidal carrier systems like liposomes. The aim of the present study was to encapsulate triethylenetetramine (TETA), a copper chelating agent, into surface modified liposomes and to investigate their permeation across the BBB. Liposomes were modified with cationized bovine serum albumin or penetratin, a cell penetrating peptide. Liposomes were characterized regarding size, PDI, zeta potential and encapsulation efficiency. Size was between 139.4±1.9nm to 171.1±3.5nm with PDI's below 0.2. Zeta potentials of vectorized liposomes were at least 6.9mV higher than those of standard liposomes. Cryo-TEM micrographs displayed liposomal structure, integrity and the similarity of structure and size between loaded, unloaded, vectorized and non- vectorized liposomes. In vivo experiments in rats showed an up to 16-fold higher brain uptake of TETA in vectorized liposomes compared to free TETA or TETA in non-vectorized liposomes, proving successful brain delivery using target seeking surface modifications. Tissue analysis indicated TETA concentrations in the brain being high enough to treat Wilson's disease.


Subject(s)
Brain/metabolism , Chelating Agents/administration & dosage , Chelating Agents/pharmacokinetics , Liposomes/administration & dosage , Liposomes/chemistry , Trientine/administration & dosage , Trientine/pharmacokinetics , Animals , Biological Availability , Carrier Proteins/chemistry , Carrier Proteins/pharmacokinetics , Cell-Penetrating Peptides , Liposomes/pharmacokinetics , Liposomes/ultrastructure , Male , Particle Size , Rats , Serum Albumin, Bovine/administration & dosage , Serum Albumin, Bovine/chemistry , Serum Albumin, Bovine/pharmacokinetics , Tissue Distribution
SELECTION OF CITATIONS
SEARCH DETAIL
...